Tuesday 20 November 2012, Amsterdam
The world market for ophthalmic drugs is a profitable segment of the healthcare market. The market for medicines to treat eye diseases is dominated by large pharma companies, which occupy five of the ten leading ophthalmic manufacturers’ positions. The others participants are specialist companies, with three focused entirely on ophthalmic pharmaceutical products. In 2011, the top 10 ophthalmic drug manufacturers accounted for 70.6% of overall world revenues in this sector. US-based manufacturers dominate the ophthalmic drug industry and market, with a new entrant, Regeneron – with its recent launch of Eylea (for wet AMD) – rapidly establishing itself in that market.
The overall ophthalmic medicines market is stimulated by a rising prevalence of eye disorders worldwide. The main causes of visual impairment and loss in the developed countries are retinal diseases, such as age-related macular degeneration (AMD), diabetic macular (o)edema, and macular (o)edema due to retinal vein occlusion. Worldwide, over 50 million patients are estimated to have AMD, with prevalence rates expected to double by 2020. Glaucoma, the leading cause of irreversible blindness, affects an estimated 70 million people worldwide. Its treatment remains one of the largest segments of the ophthalmic prescription drugs market.
Dr Syed Ahmed, a senior pharma industry analyst, said: “The top 20 ophthalmic drug manufacturers are a mix of large cap and mid cap specialist companies. Many of those companies have a long history in the industry, with some having been among the first organisations to launch eye care products. Nevertheless, several leading firms will see their places challenged over the next 10 years. Our strong revenue growth forecast for the ophthalmic drug market shows it to be an attractive proposition from 2012 to 2022, and many new entrants seek to enter that market. Clearly, too, its R&D pipeline is strong and promising.
“Analysis believe future success for ophthalmic drug manufacturers will depend on launches of new compounds, particularly neuroprotective anti-glaucoma drugs and new delivery systems and formulations, including greater use of sustained-release implant and injection technologies for retinal diseases.”
This decade many opportunities for treating eye diseases will occur, with new medicines launched. There are many opportunities for novel drugs. Pharma corporations and specialty healthcare operations will develop and prosper, analyses show.
Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 adds to a range of analytical reports on industries and markets in healthcare.
ASDReports.com contact: S. Koomen
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216
back to News
